Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report Authors: Laurenz Nagl, Lena Horvath, Arno Amann, Lorenz Schreiner, Michael Günther, Herbert Maier, Johannes Kerschbaumer, Gerlig Widmann, Danijela Minasch, Lisa-Maria Rossetti, Katharina Kostenzer, Dominik Wolf, Florian Augustin, Andreas Pircher Published: 2026 ABSTRACT BackgroundHER2 exon 20 insertions are rare oncogenic driver mutations in non-small cell lung cancer (NSCLC). Trastuzumab deruxtecan (T-DXd) has proven efficacy in pretreated metastatic HER2-mutant NSCLC. However, its use as first-line therapy in oligometastatic settings remains undocumented.Case PresentationA 66-year-old female presented with a right hilar lung mass and a singular symptomatic left frontal brain metastasis. Biopsy confirmed poorly differentiated adenocarcinoma (TTF-1 positive, PD-L1 TPS 0%) with an ERBB2 exon 20 insertion (p.Y772_A775dup). The patient declined standard chemo- and immunotherapy. An individualized treatment plan was developed, initiating off-label first-line T-DXd after resection and consolidating radiotherapy of the affected cerebral region. After four cycles of T-DXd, imaging demonstrated significant tumor reduction. Subsequent surgical resection of the primary tumor revealed a complete pathological response (ypT0N0, R0). Adjuvant T-DXd therapy was continued thereafter.ConclusionThis case illustrates the high efficacy of T-DXd as the sole first-line treatment in oligometastatic HER2-mutant NSCLC. Prospective studies are needed to systematically explore the efficacy and safety of this approach. Introduction Non-small cell lung cancer (NSCLC) harboring exon 20 insertion mutations in the gene ERBB2, also known as Human epidermal growth factor receptor 2 (HER2), is characterized by constitutive activation of the transmembrane receptor tyrosine kinase erbB-2, thus representing a distinct molecular subset with targeted treatment options.1,2 HER2 is an oncogene that is mutated or amplified in various tumor types, such as breast, gastric, and esophageal cancer. In lung cancer, mutations in or relevant amplification levels of ERBB2 are detected in about 5 % of lung adenocarcinoma.3 Activating exon 20 insertion mutations in the kinase domain of HER2 are considered an actionable genetic abnormality (AGA). Alongside monoclonal antibodies and tyrosine kinase inhibitors (TKIs), the antibody-drug conjugate (ADC) Trastuzumab deruxtecan (T-DXd) has proven its efficacy in previously treated HER2-mutant stage IV NSCLC patients, as reported in the DESTINY-Lung01 and DESTINY-Lung02 studies.4 Consequently, T-DXd is approved and routinely used for second line therapy of NSCLC patients with ERBB2 mutations. However, its application as a first-line agent, particularly in oligometastatic cases, as well as its ability to induce pathologic responses upon surgical tumor resection, has not been documented yet. Case Presentation A 66-year-old female non-smoker without a history of significant passive cigarette smoke exposure presented to the neurology department with headaches refractory to symptomatic treatment, vertigo, and mild dysphasia. Cerebral magnetic resonance imaging (cMRI) revealed a left frontal brain lesion with adjacent edema, suggestive of a singular brain metastasis from a solid cancer. Further imaging by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET-CT) showed a right hilar primary tumor (2.4 cm) and a suspicious left adrenal lesion. A multi-disciplinary tumor board (MTB) discussion opted for a primary cerebral metastasectomy to control neurological symptoms. Consequently, the frontal mass was resected via a left frontal craniotomy without relevant post-surgical complications, and the patient recovered quickly. Histological work-up revealed a central nervous system (CNS) metastasis of a poorly differentiated lung adenocarcinoma (TTF-1 positive, PD-L1 TPS 0%), which was resected in sano. Molecular profiling detected a classical gain-of-function ERBB2 exon 20 insertion (a duplication p.Y772_A775dup) in the absence of a TP53 mutation. The patient received consolidating radiotherapy to the affected cerebral area without residual or recurrent tumor manifestations during follow-up cMRI. She did not suffer from identifiable neurological or neuro-cognitive constraints secondary to the metastasectomy or radiotherapy. Detailed local tumor and lymph node (LN) staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) revealed tumor infiltration in LN 11R, corresponding to a T1c N1 local tumor stage. The initially suspected adrenal metastasis was ruled out by MRI of the abdomen (adrenal adenoma). Therefore, the situation of a locally advanced NSCLC with a single CNS metastasis was defined as oligometastatic disease according to the EORTC consensus definition of oligometastic NSCLC as defined as five or less metastases in three or less organs, which are amendable to local radical treatment.5 The final tumor stage was consequently cT1c N1 M1b (singular CNS metastasis) according to the 9th edition of the IASLC/UICC classification. Due to the otherwise very good clinical condition of the patient, the MTB recommended initiation of systemic treatment, followed by local therapy of the primary tumor in the case of sufficient tumor control as a possible conversion strategy. After thorough consultation about the various treatments, the patient declined a conventional chemo- and immunotherapy combination. Considering the oligometastatic nature of the case and the HER2 mutation, an individualized treatment plan was proposed, and based on a shared decision-making process, off-label first-line T-DXd at a dose of 5.4 mg/kg was initiated. After four cycles of treatment, imaging demonstrated significant tumor regression on CT (Figure 1). The treatment was generally well-tolerated, and the patient experienced only mild toxicity, as she developed minor nausea, abdominal discomfort, self-limiting diarrhea, and mild infectious complications (all CTCAE grade 1), as well as incomplete alopecia and brittle nails. There were no interruptions due to neutropenia and no evidence of elevated aminotransferase levels. The patient was clinically monitored for treatment-related interstitial lung disease (ILD) at every visit and by CT at an interval of three months as part of the oncological staging. Following the initial treatment plan, the patient was evaluated for local consolidation therapy, as she showed a response to systemic therapy and developed no further tumor lesions. Considering the patient’s excellent clinical condition and unimpaired pulmonary function, as well as the involvement of hilar lymph nodes, the MTB preferred lobectomy with mediastinal lymphadenectomy over conventionally fractionated radiotherapy.Figure 1Radiographic response of the right hilar tumor by T-DXd: contrast-enhanced CT-scans of the chest. (A) Baseline; (B) Follow-up after 4 cycles of T-DXd. Radiographic response of the right hilar tumor by T-DXd: contrast-enhanced CT-scans of the chest. (A) Baseline; (B) Follow-up after 4 cycles of T-DXd. Surgical right upper lobectomy and mediastinal lymphadenectomy were subsequently performed. Due to central tumor localization with enlarged and stiff hilar lymph nodes encircling the upper lobe pulmonary arteries, the minimally invasive approach was converted to open resection. Intraoperative frozen sections of the upper lobe bronchus documented tumor-free resection margins. The duration of surgery was 177 minutes; intraoperative blood loss was <100 cc without any need for blood transfusion in the perioperative period (Figure 2). The patient was sent to the regular ward on the same day. The chest drain duration was 5 days due to increased drainage volume. On the third postoperative day, the patient developed atrial fibrillation, which was successfully converted to sinus rhythm with Amiodarone. Otherwise, the postoperative course was uneventful, and the patient was discharged on day 10 after surgery. Notably, histologic work-up revealed a complete pathological response (cPR, ypT0N0, R0) of the primary tumor. All sixteen dissected lymph nodes in six mediastinal and hilar lymph node stations (3, 4, 7, 8, 9, 11R) showed no tumor infiltration. The detailed histologic work-up of the former tumor bed described a 1.5 cm measuring necrosis with extensive immune cell infiltration, including foam cell macrophages, a chronic resorptive inflammatory reaction, and fibrotic remodeling of the former tumor tissue. Structured assessment of pathologic response by using multiple slides of the tumor bed and dissected lymph nodes showed no residual tumor cells after T-Dxd treatment (Figure 3).Figure 2Video-assisted thoracoscopic surgery (VATS) of the lung cancer located in the right hilus: preparation of the hilar vessels by VATS; the size and location of the remaining tumor precluded a safe dissection of the pulmonary artery branches and finally led to conversion to thoracotomy.Figure 3Pathologic complete response (pCR) in the histologic specimen after surgical resection: Hematoxylin-eosin stain at 40x (A) and 100x (B) showing absence of remaining vital tumor cells. Necrosis is marked by white arrows, resorptive inflammation with foam cells and fibrosis is marked by black arrows. Video-assisted thoracoscopic surgery (VATS) of the lung cancer located in the right hilus: preparation of the hilar vessels by VATS; the size and location of the remaining tumor precluded a safe dissection of the pulmonary artery branches and finally led to conversion to thoracotomy. Pathologic complete response (pCR) in the histologic specimen after surgical resection: Hematoxylin-eosin stain at 40x (A) and 100x (B) showing absence of remaining vital tumor cells. Necrosis is marked by white arrows, resorptive inflammation with foam cells and fibrosis is marked by black arrows. The patient promptly recovered from surgery in the outpatient setting, and adjuvant T-DXd therapy, which was planned for one to two years, was continued thereafter. Fourteen months postoperatively, the therapy was still well tolerated, and the patient showed ongoing complete remission. As the first staging by CT was performed four months postoperatively, the patient had now formally been in CR for ten months. Recently, radiographic findings compatible with ILD (CTCAE grade 1) were detected, and T-DXd was discontinued. Follow-up cMRI and neurological examination showed sustained intracranial CR. The clinical course of the patient is summarized in Figure 4 as a timeline.Figure 4Treatment timeline: CNS RT, central nervous system radiotherapy; FUP, Follow-Up; T-DXd, Trastuzumab-Deruxtecan; 18DF-FDG-PET-CT, 18F-fluorodeoxyglucose-positron emission tomography/computed tomography Treatment timeline: CNS RT, central nervous system radiotherapy; FUP, Follow-Up; T-DXd, Trastuzumab-Deruxtecan; 18DF-FDG-PET-CT, 18F-fluorodeoxyglucose-positron emission tomography/computed tomography Discussion This case report highlights the potential of off-label T-DXd monotherapy as a first-line treatment in oligometastatic HER2-mutant NSCLC, with the potential to achieve pCR after 4 therapy cycles. The patient's refusal of standard therapies necessitated searching for an alternative treatment approach. The observed pathological complete response (pCR) supports our individualized concept of applying a sole ADC to induce a significant pathological response in an appropriate molecular NSCLC subtype. NSCLCs with ERBB2 exon 20 insertion mutations are characterized by an aggressive course as they respond poorly to systemic treatment and present with brain metastases in around 15%.6 In the case of oligometastatic lung cancer, especially with rare AGA, a clear strategy on the optimal induction treatment has not been formulated yet.7 No prospective studies on the use of HER2-targeted therapies in ERBB2 mutated localized NSCLC have been published, which necessitates individual treatment approaches. In contrast to chemo-immunotherapy, data on the potential of targeted agents to induce sustained pathological responses in oncogene-driven NSCLC are scarce. Although not directly parallel from a biological viewpoint, EGFR- and ALK-directed TKIs seem to be less capable of inducing a pathological response. For instance, the NeoADAURA (Phase 3, Osimertinib) and ALNEO study (Phase 2, Alectinib) showed major pathologic response (MPR) rates of 25% and pCR rates of 10%8 and 42% and 12%, respectively.9 Concerning HER2-specific therapies, the oral irreversible tyrosine kinase inhibitors Zongertinib10 and Sevabertinib11 showed promising efficacy in metastatic or advanced HER2-mutant NSCLC. The Beamion Lung-110 study (Phase 1/2, Zongertinib) showed an overall response rate (ORR) of 71%, and the SOHO-0111 study (Phase 1/2, Sevabertinib) documented an ORR of up to 70%; the best progression free survival (PFS) was 12.4 and 11.0 months, respectively. Despite this early data and the different situation, the use of these drugs in locally advanced and resectable NSCLC, as described in this case report, would be promising, and prospective studies in this situation are warranted. In comparison, neoadjuvant or perioperative treatment of locally advanced NSCLC without genetic drivers using chemo- and immune checkpoint inhibitor therapy is clearly more effective with regard to pCR rates, ranging from 18 to 25%,12, 13, 14 including a well-documented benefit in overall survival. Concerning T-DXd, efficacy in this context has not been evaluated specifically, however, early clinical data suggest a high efficacy of ADCs in the neoadjuvant setting. For example, the NeoCOAST-2 trial evaluated a neoadjuvant regimen combining durvalumab, single-agent platinum chemotherapy, and the TROP-2 ADC datopotamab deruxtecan and demonstrated a pCR rate of 35.2% as well as an MPR rate of 63.0%.15 To the best of our knowledge, data on the neoadjuvant use of single-agent ADCs are not available, particularly with respect to their pCR induction capacity in oligometastatic NSCLC. Applying this to the situation of oligometastatic NSCLC, especially with strong AGAs, seems highly relevant, as the most effective induction treatment is crucial for subsequent locoregional treatment. Therefore, it appears promising to develop treatment strategies that incorporate targeted treatments, either as an alternative to or in combination with chemo-immunotherapy, to utilize their potential to induce pathologic response, as pCR has repeatedly been proven to be a surrogate marker for improved long-term survival outcome in NSCLC patients.13,14 This concept is also supported by the surgical point of view, as neoadjuvant treatment with T-DXd in this single case did not result in hilar fibrosis, as often seen after standard neoadjuvant chemo-immunotherapy.16 In our case, conversion to open resection was rather due to technical reasons and enlarged lymph nodes, and a safe minimally invasive dissection of the pulmonary arteries by means of video-assisted thoracic surgery did not seem feasible. Although conversion to thoracotomy is more common in patients after neoadjuvant treatment,17 the benefit of pCR induction by neoadjuvant treatment concepts could outweigh the disadvantages of increased surgical invasiveness in this setting. Conclusion This case highlights a single case report using T-DXd as first-line therapy in oligometastatic HER2-mutant NSCLC, leading to complete pathological remission, although with relatively short follow-up. This demonstrates the principal efficacy of T-DXd as monotherapy or as a combination partner and may be hypothesis-generating for the development of chemo-immunotherapy concepts in individualized treatment strategies for oligometastatic patients. However, a natural selection bias has to be acknowledged for the report of a single case, and the presumably favorable tumor biology of oligometastatic disease has to be considered accordingly. As data on T-DXd treatment of locally advanced NSCLC with activating mutations in HER2 are lacking, prospective clinical trials are warranted. CRediT Authorship Contribution Statement Laurenz Nagl: Conceptualization, Writing - Original Draft, Investigation, Visualization. Lena Horvath: Investigation, Writing - review & editing. Arno Amann: Investigation, Writing - review & editing. Lorenz Schreiner: Investigation, Visualization, Formal analysis, Writing - review & editing. Michael Günther: Investigation, Writing - review & editing. Herbert Maier: Investigation, Writing - review & editing. Johannes Kerschbaumer: Investigation, Writing - review & editing. Gerlig Widmann: Formal analysis, Investigation, Visualization, Writing - review & editing. Danijela Minasch: Investigation, Writing - review & editing. Lisa-Maria Rossetti: Investigation, Writing - review & editing. Katharina Kostenzer: Investigation, Writing - review & editing. Dominik Wolf: Writing - review & editing, Supervision. Florian Augustin: Conceptualization, Investigation, Visualization, Supervision, Writing -review & editing. Andreas Pircher: Conceptualization, Investigation, Supervision, Writing - review & editing. Disclosure All authors disclose that they have no conflicts of interest in relation to the article.